nVerses Capital’s 10x Genomics TXG Stock Holding History

nVerses Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,100	Closed	-$21.4K	–	1397
2024 Q2	$21.4K	Buy	+1,100	New	+$28.8K	0.01%	783

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

nVerses Capital's TXG Position: Q3 2024 in Review

nVerses Capital sold out of 10x Genomics (TXG) in Q3 2024, closing a stake of 1,100 shares — an estimated $21.4K sold.

nVerses Capital first reported a position in TXG in Q2 2024 and held it in 1 quarter. The position peaked at $21.4K in Q2 2024. 266 funds tracked by Wall St. Rank hold TXG as of Q3 2024.

nVerses Capital reported no remaining 10x Genomics position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 1,100 10x Genomics shares in Q3 2024, an estimated $21.4K.
nVerses Capital first reported a position in 10x Genomics in Q2 2024 and held it in 1 quarter.
nVerses Capital's 10x Genomics position peaked at $21.4K in Q2 2024.
266 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.